Who Paid My Doc
Roman Schwartsman
Orthopaedic Surgery Boise, ID Medical Doctor
NPI 1356378723 CMS profile 106287
6590 Norwood Dr, Boise, ID 83704
General payments
$358,453
Research payments
$0
Ownership & investment interest
$2,613,404
Through program year 2025, Roman Schwartsman of Boise, ID is reported in the CMS Open Payments database as having received $358,453 across 10 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $2,613,404 across 12 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 96th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $11,184 | 2 | |
| 2024 | General | $647 | 2 | |
| 2023 | General | $25,969 | 3 | |
| 2022 | General | $320,539 | 2 | |
| 2021 | General | $114 | 1 | |
| 2025 | Ownership | $919,816 | 3 | |
| 2024 | Ownership | $426,712 | 2 | |
| 2023 | Ownership | $426,712 | 2 | |
| 2022 | Ownership | $185,640 | 1 | |
| 2021 | Ownership | $457,873 | 2 | |
| 2020 | Ownership | $140,400 | 1 | |
| 2019 | Ownership | $56,250 | 1 |
Beside peers
- Roman Schwartsman
- Orthopaedic Surgery median
- Middle half of Orthopaedic Surgery
- National median
In program year 2025, general payments to Roman Schwartsman were reported at $11,184. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.
Show as a table
| Year | Roman Schwartsman | Orthopaedic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $644 | $140–$2,844 | $163 |
| 2020 | $0 | $312 | $75–$1,860 | $114 |
| 2021 | $114 | $520 | $117–$2,495 | $132 |
| 2022 | $320,539 | $598 | $128–$2,731 | $149 |
| 2023 | $25,969 | $461 | $128–$2,264 | $160 |
| 2024 | $647 | $497 | $134–$2,475 | $164 |
| 2025 | $11,184 | $563 | $147–$2,717 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 26 billing codesPaid by Medicare
$19,342
Medicare patients
48
Services billed
168
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 63% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
10 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Orthopaedic Surgery in Idaho
Related records
Orthopaedic Surgery in Idaho
Practitioners in the same specialty and state, ranked by reported value.
All Orthopaedic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Idaho
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.